Amphastar Pharmaceuticals Stock News

Eli Lilly and Co (NYSE:LLY) revealed that it will sell Baqsimi, its nasal treatment for severe hypoglycemia in people with diabetes, to Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for around $1 billio

Shares of Eli Lilly & Co. LLY gained 0.5% in premarket trading Monday, after the drugmaker announced an agreement to sell its hypoglycemia treatment for people with diabetes Baqsimi to Amphastar Pharm

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 24, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will provide a Business update and hold a Conference call today, Monday, A

Amphastar Pharmaceuticals (AMPH), Alpha Metallurgical Resources (AMR) and Riley Exploration Permian (REPX) have been selected as the top picks with a high net income ratio.

This drug stock gained 35% since its earnings report. The biotech got FDA approval for its opioid overdose nasal spray.

Amphastar (AMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 12, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Jacob Liawatidewi, EVP of Corporate Administration, Tony Marrs

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Expectations for the next FOMC meeting have seen odds of a 50bps rate hike go from extremely unlikely to highly likely

Here is how Amphastar Pharmaceuticals (AMPH) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

The company reported a record revenue year and increased EPS.

Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Bill Peters - Chief Financial Officer, Treasurer, Executive Vice Presi